The Shane DiGiovanna Act requires the Department of Health and Human Services to run a two-year nationwide demonstration program testing whether Medicaid must cover wound care treatments for patients with epidermolysis bullosa, a rare genetic skin disorder. The covered items include over-the-counter pain relievers and antihistamines, antiseptics, antibiotic ointments, and specialized wound dressings and supplies. The program must begin within one year of the bill's enactment and apply to eligible Medicaid beneficiaries in all states. Within one year after the demonstration ends, the agency must report to Congress on the program's effects on healthcare spending and patient outcomes, along with recommendations for preventing hospitalizations related to this condition.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.